Skip to main content
Oxford University Hospitals NHS Foundation Trust

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

First UK COVID-19 vaccine study for pregnant women launched in Oxford

01/06/2021

The first COVID-19 vaccine study in the UK recruiting pregnant women has been launched in Oxford.

The phase 2/3 study aims to further understand the safety, tolerability and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in healthy pregnant women, with approximately 235 volunteers involved throughout the UK, including 10 in Oxford.

Following updated guidance from the Joint Committee on Vaccination and Immunisation (JCVI) released in April 2021, pregnant women are now offered approved COVID-19 vaccines at the same time as the rest of the UK population, based on their age and clinical risk group. 

Recruitment will begin this week at the John Radcliffe Hospital. The study was launched in the UK in May 2021 and has been running in the US since February 2021.

Data from the United States, where more than 100,000 pregnant women have been vaccinated (mainly with mRNA vaccines, including Pfizer-BioNTech), has not revealed any safety concerns raised.

The role of this placebo-controlled study (COVID-19 Vacc Maternal Immunisation) is to provide more robust information on the vaccine immune response in pregnancy, as well as safety reporting and the potential transfer of maternal antibodies to infants.

Each participant enrolled in the study will initially receive either two doses of the vaccine or a placebo 21 days apart. All participants will be told whether they received the vaccine or placebo one month after giving birth, and those who were given the placebo jab (a salt water solution that does not contain any active ingredients) will receive the Pfizer-BioNTech COVID-19 vaccine.

Research participants will be required to answer questionnaires about their health, provide blood samples, complete an e-diary and will receive extra monitoring while on the study, compared to those who receive a vaccine through the rollout.

All volunteers will need to visit their site for four planned visits before their baby is born and then two more follow-up appointments after the baby is born. The study is looking for women who are around 30 weeks pregnant to take part. This is to ensure that pregnant women who receive the placebo as part of the study will not have to wait long to be offered the active vaccine after their baby is born.

Participants for the study will be identified via obstetricians and midwives at the hospital sites involved, with the study doctor determining whether each pregnant woman and their unborn baby would be suitable. Participation in the study is completely voluntary and participants can leave the study at any time.

Prof Manu Vatish, Consultant Obstetrician at Oxford University Hospitals and Senior Clinical Fellow with the University of Oxford's Nuffield Department of Women's and Reproductive Health, said: "We are delighted to be taking part in this important study which is crucial to help us understand both the safety and immunogenicity of the Pfizer-BioNTech vaccine for pregnant women and their children.

"We know that approved COVID-19 vaccines are safe for pregnant women as per JCVI guidance, but this will add valuable information to our knowledge of how these vaccines work."

Professor Andrew Ustianowski, National Clinical Lead for the UK NIHR COVID Vaccine Research Programme, said: "We want to ensure we provide the data to guide the best way of protecting and vaccinating our entire population. This includes pregnant women and I am excited that this study is commencing as there are important questions still to be answered.

"The extra monitoring involved being a participant in this study, along with the possibility of some pregnant women receiving a licensed and effective COVID vaccine before they would be through the national rollout, is something we hope will attract potential volunteers to this important study."